Opus Genetics Wins FDA Approval for Ryzumvi to Treat Presbyopia in Adults
Opus Genetics secured FDA clearance for Ryzumvi, phentolamine ophthalmic solution 0.75%, to treat presbyopia in adults, expanding its U.S. indications. Already reported Phase 3 VEGA-2 and VEGA-3 results met all primary and key secondary efficacy goals, with no treatment-related serious adverse events. The presbyopia ap